XML 107 R93.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and contingencies - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Apr. 29, 2020
Aug. 01, 2018
May 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
May 29, 2020
Aug. 23, 2018
Apr. 20, 2017
Jun. 30, 2016
Other Commitments                    
Contingent liability, cancellation and forfeiture $ 211.6                  
Akcea                    
Other Commitments                    
Upfront licensing fee   $ 12.0 $ 6.0   $ 6.0 $ 12.0        
Milestone payments         4.0          
Akcea | Maximum                    
Other Commitments                    
Milestone payments       $ 4.0            
Censa                    
Other Commitments                    
Asset acquisition, milestone, amount             $ 217.5      
Asset acquisition, development and regulatory milestones             109.0      
Asset acquisition, net sales milestone             160.0      
Asset acquisition, initial milestone             $ 30.0      
Agilis Merger Agreement | Marathon Pharmaceuticals, LLC                    
Other Commitments                    
Development milestone payment obligations                 $ 50.0  
Agilis Merger Agreement | Akcea                    
Other Commitments                    
Milestone payments     $ 6.0   $ 4.0          
Agilis                    
Other Commitments                    
Development milestone payment obligations       40.0            
Development milestone payments which the entity is obligated to pay       40.0            
Net sales amount $ 150.0                  
Development milestone obligation payments made       $ 2.4            
Agilis | Minimum                    
Other Commitments                    
Product sales (as a percent) 2.00%     2.00%            
Agilis | Maximum                    
Other Commitments                    
Development milestone payment obligations       $ 60.0            
Development milestone payments which the entity is obligated to pay $ 20.0                  
Priority review voucher amount       535.0            
Net sales amount $ 150.0     $ 150.0            
Product sales (as a percent) 6.00%     6.00%            
Development milestone payment obligations, net of cancellation and forfeiture       $ 20.0            
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture $ 361.0     361.0            
Agilis | Agilis Merger Agreement                    
Other Commitments                    
Development milestone payment obligations       40.0       $ 40.0    
Agilis | Agilis Merger Agreement | Maximum                    
Other Commitments                    
Development milestone payment obligations       60.0            
Priority review voucher amount       535.0            
Agilis | Rights Exchange Agreement                    
Other Commitments                    
Contingent liability cancellation and forfeiture of potential milestone payments       174.0            
Development milestone payment obligations, cancellation and forfeiture       37.6            
Contingent liability, cancellation and forfeiture       211.6            
BioElectron | Maximum                    
Other Commitments                    
Development milestone payment obligations       200.0            
Net product revenue | Wellcome Trust                    
Other Commitments                    
Development milestone payment obligations                   $ 0.8
Net product revenue | Wellcome Trust | Maximum                    
Other Commitments                    
Development milestone payment obligations       $ 22.4